Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PGD | P52209 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PPM1B | O75688 | 1/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12826506 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL10266772 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL2749036 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL9979878 | 1.00 | ALDH1A1 (0.47) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL18219200 | 0.91 | ALDH1A1 (0.42) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL2526095 | 0.91 | MAPT (0.42) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL17885970 | 0.91 | ALDH1A1 (0.42) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL527434 | 0.91 | MAPT (0.42) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL17885973 | 0.91 | ALDH1A1 (0.42) | ALDH1A1MAPTITGA4MAPK1NPSR1 | |
| SCHEMBL13587126 | 0.91 | MAPT (0.42) | ALDH1A1MAPTITGA4MAPK1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025053792-A1 | COLLECTIVE SYNTHESIS OF PHANTOMOLIN FAMILY THROUGH TOTAL SYNTHESIS OF THE SESQUITERPENE LACTONE MOLEPHANTIN | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-03-13 | — | — | WO | disclosed |
| CN-114380733-B | Chiral beta-amino acid derivative and preparation method thereof | 常州大学 | 2024-01-26 | — | — | CN | disclosed |
| CN-114380733-A | Chiral beta-amino acid derivative and preparation method thereof | 常州大学 | 2022-04-22 | — | — | CN | disclosed |
| US-10765648-B2 | iNKT cell modulators and methods of using the same | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2020-09-08 | — | — | US | disclosed |
| EP-2785683-B1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | LUDWIG INST FOR CANCER RES LTD (CH) | 2020-02-05 | — | — | EP | disclosed |
| US-10314796-B2 | iNKT cell modulators and methods of using the same | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2019-06-11 | — | — | US | disclosed |
| US-9708285-B2 | Dioxolane derivative, liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2017-07-18 | — | — | US | disclosed |
| US-9700532-B2 | iNKT cell modulators and methods of using the same | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2017-07-11 | — | — | US | disclosed |
| US-20160361280-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2016-12-15 | — | — | US | disclosed |
| US-20160185746-A1 | DIOXOLANE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LAB (JP) | 2016-06-30 | — | — | US | disclosed |
| US-5674531-A | CONTROLLED DRUG DELIVERY, BIODEGRADATION, NONAGGREGATING | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-10-07 | — | — | US | disclosed |
| US-5656660-A | AMINE OR GUANIDINE GROUP-CONTAINING TRYPTASE INHIBITOR | ARRIS PHARMACEUTICAL CORPORATION (US) | 1997-08-12 | — | — | US | disclosed |
| US-5613494-A | ULTRASONIC CONTRAST AGENT, MICROPARTICLES CONTAINING A GAS | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5505784-A | Polycondensates which contain tartaric acid derivatives, processes for their preparation and use thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-09 | — | — | US | disclosed |
| EP-0648769-A1 | 12-Hetero-substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizium salts and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1995-04-19 | — | — | EP | disclosed |
| US-5391696-A | Biodegradable polyesters and polyamides for sustained drug delivery and as ultrasonic contrast agents in medical diagnosis, particularly blood circulation of the heart | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-02-21 | — | — | US | disclosed |
| US-5380729-A | Treatment or prevention of neurodegenerative disorders or neurotoxic injuries | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0222522-B1 | PLATINUM COORDINATION COMPOUNDS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1990-03-14 | — | — | EP | disclosed |
| US-4783452-A | ANTITUMOR AGENTS | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1988-11-08 | — | — | US | disclosed |
| EP-0222522-A2 | Platinum coordination compounds | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 1987-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160361280-A1 | INKT CELL MODULATORS AND METHODS OF USING THE SAME | PBK, NFATC1, UGCG | ALDH1A1 1769/4885MAPT 4703/4885ITGA4 748/4885 |
| US-10765648-B2 | iNKT cell modulators and methods of using the same | PBK, NFATC1, UGCG | ALDH1A1 1769/4885MAPT 4703/4885ITGA4 748/4885 |
| US-10314796-B2 | iNKT cell modulators and methods of using the same | PBK, NFATC1, UGCG | ALDH1A1 1769/4885MAPT 4703/4885ITGA4 748/4885 |
| US-20160185746-A1 | DIOXOLANE DERIVATIVE, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | DRD1, SFXN1, CCND1 | ALDH1A1 571/4885MAPT 1842/4885ITGA4 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.